2‑Cl‑IB‑MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines

Kotulova,Jana; Lonova,Katerina; Kubickova,Agata; Vrbkova,Jana; Kourilova,Pavla; Hajduch,Marian; Dzubak,Petr

doi:10.3892/ijmm.2022.5086

2‑Cl‑IB‑MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines

Authors:
- Jana Kotulova
- Katerina Lonova
- Agata Kubickova
- Jana Vrbkova
- Pavla Kourilova
- Marian Hajduch
- Petr Dzubak
View Affiliations

Affiliations: Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
Published online on: January 18, 2022 https://doi.org/10.3892/ijmm.2022.5086
Article Number: 31
Copyright: © Kotulova et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Specific A3 adenosine receptor (A3AR) agonist, 2‑chloro‑N6‑(3‑iodobenzyl)‑5'‑N‑methylcarboxamidoadenosine (2‑Cl‑IB‑MECA), demonstrates anti‑proliferative effects on various types of tumor. In the present study, the cytotoxicity of 2‑Cl‑IB‑MECA was analyzed in a panel of tumor and non‑tumor cell lines and its anticancer mechanisms in JoPaca‑1 pancreatic and Hep‑3B hepatocellular carcinoma cell lines were also investigated. Initially, decreased tumor cell proliferation, cell accumulation in the G1 phase and inhibition of DNA and RNA synthesis was found. Furthermore, western blot analysis showed decreased protein expression level of β‑catenin, patched1 (Ptch1) and glioma‑associated oncogene homolog zinc finger protein 1 (Gli1), which are components of the Wnt/β‑catenin and Sonic hedgehog/Ptch/Gli transduction pathways. In concordance with these findings, the protein expression levels of cyclin D1 and c‑Myc were reduced. Using a luciferase assay, it was revealed for the first time a decrease in β‑catenin transcriptional activity, as an early event following 2‑Cl‑IB‑MECA treatment. In addition, the protein expression levels of multidrug resistance‑associated protein 1 and P‑glycoprotein (P‑gp) were reduced and the P‑gp xenobiotic efflux function was also reduced. Next, the enhancing effects of 2‑Cl‑IB‑MECA on the cytotoxicity of conventional chemotherapy was investigated. It was found that 2‑Cl‑IB‑MECA enhanced carboplatin and doxorubicin cytotoxic effects in the JoPaca‑1 and Hep‑3B cell lines, and a greater synergy was found in the highly tumorigenic JoPaca‑1 cell line. This provides a novel in vitro rationale for the utilization of 2‑Cl‑IB‑MECA in combination with chemotherapeutic agents, not only for hepatocellular carcinoma, but also for pancreatic cancer. Other currently used conventional chemotherapeutics, fluorouracil and gemcitabine, showed synergy only when combined with high doses of 2‑Cl‑IB‑MECA. Notably, experiments with A₃AR‑specific antagonist, N‑[9‑Chloro‑2‑(2‑furanyl)(1,2,4)‑triazolo(1,5‑c)quinazolin‑5‑yl]benzene acetamide, revealed that 2‑Cl‑IB‑MECA had antitumor effects via both A3AR‑dependent and ‑independent pathways. In conclusion, the present study identified novel antitumor mechanisms of 2‑Cl‑IB‑MECA in pancreatic and hepatocellular carcinoma in vitro that further underscores the importance of A3AR agonists in cancer therapy.

View Figures

View References

1	Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I and Bray F: Global cancer observatory: Cancer today. Lyon, France: International Agency for Research on Cancer; 2020, Available from: https://gco.iarc.fr/today. Accessed November 24, 2021.
2	Rawla P, Sunkara T and Gaduputi V: Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J Oncol. 10:10–27. 2019. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, Kitade M, Domínguez MP, Castven D, Breuhahn K, Conner EA, et al: Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. J Hepatol. 63:661–669. 2015. View Article : Google Scholar :
5	Zeng SY, Pottler M, Lan B, Grutzmann R, Pilarsky C and Yang H: Chemoresistance in pancreatic cancer. Int J Mol Sci. 20:45042019. View Article : Google Scholar
6	Adamska A and Falasca M: ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? World J Gastroenterol. 24:3222–3238. 2018. View Article : Google Scholar : PubMed/NCBI
7	Lohitesh K, Chowdhury R and Mukherjee S: Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: An insight. Cancer Cell Int. 18:442018. View Article : Google Scholar
8	Liu A, Wu Q, Peng D, Ares I, Anadón A, Lopez-Torres B, Martínez-Larrañaga MR, Wang X and Martínez MA: A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation. Med Res Rev. 40:1973–2018. 2020. View Article : Google Scholar : PubMed/NCBI
9	Man S, Lu Y, Yin L, Cheng X and Ma L: Potential and promising anticancer drugs from adenosine and its analogs. Drug Discov Today. 26:1490–1500. 2021. View Article : Google Scholar
10	Fredholm BB, IJzerman AP, Jacobson KA, Linden J and Müller CE: International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev. 63:1–34. 2011. View Article : Google Scholar : PubMed/NCBI
11	Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger A, Ohana G, Harish A, Merimski O, Barer F and Fishman P: The A3 adenosine receptor is highly expressed in tumor versus normal cells: Potential target for tumor growth inhibition. Clin Cancer Res. 10:4472–4479. 2004. View Article : Google Scholar
12	Morello S, Petrella A, Festa M, Popolo A, Monaco M, Vuttariello E, Chiappetta G, Parente L and Pinto A: Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation. Cancer Biol Ther. 7:278–284. 2008. View Article : Google Scholar
13	Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle L and Fishman P: The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol. 33:287–295. 2008.PubMed/NCBI
14	Gessi S, Cattabriga E, Avitabile A, Gafa' R, Lanza G, Cavazzini L, Bianchi N, Gambari R, Feo C, Liboni A, et al: Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res. 10:5895–5901. 2004. View Article : Google Scholar : PubMed/NCBI
15	Kim HO, Ji XD, Siddiqi SM, Olah ME, Stiles GL and Jacobson KA: 2-Substitution of N6-benzyladenosine-5′-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem. 37:3614–3621. 1994. View Article : Google Scholar : PubMed/NCBI
16	Van Schaick EA, Jacobson KA, Kim HO, Ijzerman AP and Danhof M: Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur J Pharmacol. 308:311–314. 1996. View Article : Google Scholar
17	Wittendorp MC, Biber K and Boddeke HWGM: CL-IB-MECA induced release of CCL2 by astrocytes: Possible role for the adenosine A3 receptor? Naunyn-Schmiedeb Arch Pharmacol. 369:R1782004.
18	Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ and Auchampach JA: Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl) adenosine-5′-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor. J Pharmacol Exp Ther. 319:1200–1210. 2006. View Article : Google Scholar : PubMed/NCBI
19	Coppi E, Cherchi F, Fusco I, Failli P, Vona A, Dettori I, Gaviano L, Lucarini E, Jacobson KA, Tosh DK, et al: Adenosine A3 receptor activation inhibits pronociceptive N-type Ca²⁺ currents and cell excitability in dorsal root ganglion neurons. Pain. 160:1103–1118. 2019. View Article : Google Scholar : PubMed/NCBI
20	Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA and Fishman P: CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol. 226:2438–2447. 2011. View Article : Google Scholar
21	Morello S, Sorrentino R, Montinaro A, Luciano A, Maiolino P, Ngkelo A, Arra C, Adcock IM and Pinto A: NK1.1 cells and CD8 T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model. Neoplasia. 13:365–373. 2011. View Article : Google Scholar : PubMed/NCBI
22	Bar Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Perez-Liz G, Del Valle L and Fishman P: Effect of CF102 on growth suppression and apoptosis in an orthotopic model of hepatocellular carcinoma. J Clin Oncol. 26(Suppl 15): S221132008. View Article : Google Scholar
23	Safadi R, Braun M, Francis A, Milgrom Y, Massarwa M, Hakimian D, Hazou W, Issachar A, Harpaz Z, Farbstein M, et al: Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. Aliment Pharmacol Ther. 54:1405–1415. 2021. View Article : Google Scholar : PubMed/NCBI
24	Stemmer SM, Manojlovic NS, Marinca MV, Petrov P, Cherciu N, Ganea D, Ciuleanu TE, Puscas IA, Beg MS, Purcell WT, et al: A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC). J Clin Oncol. 37(Suppl 15): S25032019. View Article : Google Scholar
25	Stemmer SM, Manojlovic NS, Marinca MV, Petrov P, Cherciu N, Ganea D, Ciuleanu TE, Pusca IA, Beg MS, Purcell WT, et al: Namodenoson in advanced hepatocellular carcinoma and Child-Pugh B cirrhosis: Randomized placebo-controlled clinical trial. Cancers (Basel). 13:1872021. View Article : Google Scholar
26	Ohana G, Cohen S, Rath-Wolfson L and Fishman P: A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy. Mol Med Rep. 14:4335–4341. 2016. View Article : Google Scholar : PubMed/NCBI
27	David M, Gospodinov DK, Gheorghe N, Mateev GS, Rusinova MV, Hristakieva E, Solovastru LG, Patel RV, Giurcaneanu C, Hitova MC, et al: Treatment of plaque-type psoriasis with oral CF101: Data from a phase II/III multicenter, randomized, controlled trial. J Drugs Dermatol. 15:931–938. 2016.PubMed/NCBI
28	Storme J, Tosh DK, Gao ZG, Jacobson KA and Stove CP: Probing structure-activity relationship in β-arrestin2 recruitment of diversely substituted adenosine derivatives. Biochem Pharmacol. 158:103–113. 2018. View Article : Google Scholar : PubMed/NCBI
29	Suresh RR, Jain S, Chen Z, Tosh DK, Ma Y, Podszun MC, Rotman Y, Salvemini D and Jacobson KA: Design and in vivo activity of A₃ adenosine receptor agonist prodrugs. Purinergic Signal. 16:367–377. 2020. View Article : Google Scholar :
30	Pottie E, Tosh DK, Gao ZG, Jacobson KA and Stove CP: Assessment of biased agonism at the A₃ adenosine receptor using β-arrestin and miniGα_i recruitment assays. Biochem Pharmacol. 177:1139342020. View Article : Google Scholar
31	Kim SJ, Min HY, Chung HJ, Park EJ, Hong JY, Kang YJ, Shin DH, Jeong LS and Lee SK: Inhibition of cell proliferation through cell cycle arrest and apoptosis by thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, in human lung cancer cells. Cancer Lett. 264:309–315. 2008. View Article : Google Scholar
32	Baltos JA, Paoletta S, Nguyen AT, Gregory KJ, Tosh DK, Christopoulos A, Jacobson KA and May LT: Structure-activity analysis of biased agonism at the human adenosine A3 receptor. Mol Pharmacol. 90:12–22. 2016. View Article : Google Scholar : PubMed/NCBI
33	Vecchio EA, Baltos JA, Nguyen ATN, Christopoulos A, White PJ and May LT: New paradigms in adenosine receptor pharmacology: Allostery, oligomerization and biased agonism. Br J Pharmacol. 175:4036–4046. 2018. View Article : Google Scholar :
34	Fredebohm J, Boettcher M, Eisen C, Gaidaμ M, Heller A, Keleg S, Tost J, Greulich-Bode KM, Hotz-Wagenblatt A, Lathrop M, et al: Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system. PLoS One. 7:e485032012. View Article : Google Scholar
35	Novak I, Yu H, Magni L and Deshar G: Purinergic signaling in pancreas-from physiology to therapeutic strategies in pancreatic cancer. Int J Mol Sci. 21:87812020. View Article : Google Scholar
36	Qiu GH, Xie X, Xu F, Shi XH, Wang Y and Deng L: Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B. Cytotechnology. 67:1–12. 2015. View Article : Google Scholar :
37	Torres A, Vargas Y, Uribe D, Jaramillo C, Gleisner A, Salazar-Onfray F, López MN, Melo R, Oyarzún C, San Martín R and Quezada C: Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells. Oncotarget. 7:67373–67386. 2016. View Article : Google Scholar
38	Torres Á, Erices JI, Sanchez F, Ehrenfeld P, Turchi L, Virolle T, Uribe D, Niechi I, Spichiger C, Rocha JD, et al: Extracellular adenosine promotes cell migration/invasion of glioblastoma stem-like cells through A₃ Adenosine Receptor activation under hypoxia. Cancer Lett. 446:112–122. 2019. View Article : Google Scholar : PubMed/NCBI
39	Montraveta A, Xargay-Torrent S, López-Guerra M, Rosich L, Pérez-Galán P, Salaverria I, Beà S, Kalko SG, de Frias M, Campàs C, et al: Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma. Oncotarget. 5:726–739. 2014. View Article : Google Scholar :
40	Fishman P, Bar-Yehuda S, Barer F, Madi L, Multani AS and Pathak S: The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res. 269:230–236. 2001. View Article : Google Scholar
41	Soares AS, Costa VM, Diniz C and Fresco P: The combination of Cl-IB-MECA with paclitaxel: A new anti-metastatic therapeutic strategy for melanoma. Cancer Chemother Pharmacol. 74:847–860. 2014. View Article : Google Scholar : PubMed/NCBI
42	Soares AS, Costa VM, Diniz C and Fresco P: Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma. Biomed Pharmacother. 67:777–789. 2013. View Article : Google Scholar : PubMed/NCBI
43	Mlejnek P, Dolezel P and Kosztyu P: P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N6-(3-io dobenzyl)-adenosine-5′-n-methyluronamide in human leukemia cells. J Cell Physiol. 227:676–685. 2012. View Article : Google Scholar
44	Abel B, Tosh DK, Durell SR, Murakami M, Vahedi S, Jacobson KA and Ambudkar SV: Evidence for the interaction of A₃ adenosine receptor agonists at the drug-binding site(s) of human P-glycoprotein (ABCB1). Mol Pharmacol. 96:180–192. 2019. View Article : Google Scholar : PubMed/NCBI
45	Noskova V, Dzubak P, Kuzmina G, Ludkova A, Stehlik D, Trojanec R, Janostakova A, Korinkova G, Mihal V and Hajduch M: In vitro chemoresistance profile and expression/function of MDR associated proteins in resistant cell lines derived from CCRF-CEM, K562, A549 and MDA MB 231 parental cells. Neoplasma. 49:418–425. 2002.
46	Le Poul E, Hisada S, Mizuguchi Y, Dupriez VJ, Burgeon E and Detheux M: Adaptation of aequorin functional assay to high throughput screening. J Biomol Screen. 7:57–65. 2002. View Article : Google Scholar : PubMed/NCBI
47	Borková L, Frydrych I, Jakubcová N, Adámek R, Lišková B, Gurská S, Medvedíková M, Hajdúch M and Urban M: Synthesis and biological evaluation of triterpenoid thiazoles derived from betulonic acid, dihydrobetulonic acid, and ursonic acid. Eur J Med Chem. 185:1118062020. View Article : Google Scholar
48	Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58:621–681. 2006. View Article : Google Scholar : PubMed/NCBI
49	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar
50	Bourderioux A, Naus P, Perlíková P, Pohl R, Pichová I, Votruba I, Dzubák P, Konecný P, Hajdúch M, Stray KM, et al: Synthesis and significant cytostatic activity of 7-hetaryl-7-deazaadenosines. J Med Chem. 54:5498–5507. 2011. View Article : Google Scholar : PubMed/NCBI
51	Schneider CA, Rasband WS and Eliceiri KW: NIH image to imageJ: 25 Years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
52	Dzubák P, Hajdúch M, Gazák R, Svobodová A, Psotová J, Walterová D, Sedmera P and Kren V: New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg Med Chem. 14:3793–3810. 2006. View Article : Google Scholar
53	Borea PA, Varani K, Vincenzi F, Baraldi PG, Tabrizi MA, Merighi S and Gessi S: The A3 adenosine receptor: History and perspectives. Pharmacol Rev. 67:74–102. 2015. View Article : Google Scholar
54	Laudadio MA and Psarropoulou C: The A3 adenosine receptor agonist 2-Cl-IB-MECA facilitates epileptiform discharges in the CA3 area of immature rat hippocampal slices. Epilepsy Res. 59:83–94. 2004. View Article : Google Scholar : PubMed/NCBI
55	Jafari SM, Panjehpour M, Aghaei M, Joshaghani HR and Enderami SE: A3 adenosine receptor agonist inhibited survival of breast cancer stem cells via GLI-1 and ERK1/2 pathway. J Cell Biochem. 118:2909–2920. 2017. View Article : Google Scholar : PubMed/NCBI
56	Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S and Borea PA: A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem. 280:19516–19526. 2005. View Article : Google Scholar
57	Borea PA, Gessi S, Merighi S, Vincenzi F and Varani K: Pharmacology of adenosine receptors: The state of the art. Physiol Rev. 98:1591–1625. 2018. View Article : Google Scholar : PubMed/NCBI
58	Haines K, Sarabia SF, Alvarez KR, Tomlinson G, Vasudevan SA, Heczey AA, Roy A, Finegold MJ, Parsons DW, Plon SE, et al: Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. Pediatr Blood Cancer. 66:e277452019. View Article : Google Scholar : PubMed/NCBI
59	Jones S, Zhang XS, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
60	Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar : PubMed/NCBI
61	Ding J, Zhou XT, Zou HY and Wu J: Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter. Lab Invest. 97:819–832. 2017. View Article : Google Scholar
62	He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science. 281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
63	Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:422–426. 1999. View Article : Google Scholar : PubMed/NCBI
64	Spoelstra EC, Westerhoff HV, Pinedo HM, Dekker H and Lankelma J: The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur J Biochem. 221:363–373. 1994. View Article : Google Scholar : PubMed/NCBI
65	Queiroz KCS, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP and Spek CA: Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene. 29:6314–6322. 2010. View Article : Google Scholar
66	Jacobson KA: Adenosine A3 receptors: Novel ligands and paradoxical effects. Trends Pharmacol Sci. 19:184–191. 1998. View Article : Google Scholar : PubMed/NCBI
67	Aghaei M, Panjehpour M, Karami-Tehrani F and Salami S: Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: Involvement of intrinsic pathway. J Cancer Res Clin Oncol. 137:1511–1523. 2011. View Article : Google Scholar
68	Gao ZG and Jacobson KA: Translocation of arrestin induced by human A3 adenosine receptor ligands in an engineered cell line: Comparison with G protein-dependent pathways. Purinergic Signal. 4:S78–S79. 2008.
69	Mundell S and Kelly E: Adenosine receptor desensitization and trafficking. Biochim Biophys Acta. 1808:1319–1328. 2011. View Article : Google Scholar
70	Hu J, Nakano H, Sakurai H and Colburn NH: Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells. Carcinogenesis. 25:1991–2003. 2004. View Article : Google Scholar : PubMed/NCBI
71	De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2): S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
72	Hasnain SZ, Lourie R, Das I, Chen AC and McGuckin MA: The interplay between endoplasmic reticulum stress and inflammation. Immunol Cell Biol. 90:260–270. 2012. View Article : Google Scholar : PubMed/NCBI
73	Tam AB, Mercado EL, Hoffmann A and Niwa M: ER stress activates NF-κB by integrating functions of basal IKK activity, IRE1 and PERK. PLoS One. 7:e450782012. View Article : Google Scholar
74	Makhov P, Naito S, Haifler M, Kutikov A, Boumber Y, Uzzo RG and Kolenko VM: The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell Death Dis. 9:3742018. View Article : Google Scholar
75	Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P and Hemmings BA: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15:6541–6551. 1996. View Article : Google Scholar
76	Vincent EE, Elder DJ, Thomas EC, Phillips L, Morgan C, Pawade J, Sohail M, May MT, Hetzel MR and Tavaré JM: Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer. 104:1755–1761. 2011. View Article : Google Scholar : PubMed/NCBI
77	Yung HW, Charnock-Jones DS and Burton GJ: Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLoS One. 6:e178942011. View Article : Google Scholar :
78	Wu LF, Wei BL, Guo YT, Ye YQ, Li GP, Pu ZJ and Feng JL: Apoptosis induced by adenosine involves endoplasmic reticulum stress in EC109 cells. Int J Mol Med. 30:797–804. 2012. View Article : Google Scholar : PubMed/NCBI
79	Nie J, Liu A, Tan Q, Zhao K, Hu K, Li Y, Yan B and Zhou L: AICAR activates ER stress-dependent apoptosis in gallbladder cancer cells. Biochem Biophys Res Commun. 482:246–252. 2017. View Article : Google Scholar
80	Ding L and Billadeau DD: Glycogen synthase kinase-3β: A novel therapeutic target for pancreatic cancer. Expert Opin Ther Targets. 24:417–426. 2020. View Article : Google Scholar : PubMed/NCBI
81	Fishman P, Bar Yehuda S, Stemmer SM and Madi L: CF101 enhances the apoptotic effect of chemotherapy on colon and pancreatic carcinoma cell lines: Molecular mechanisms involved. J Clin Oncol. 22(Suppl 14): S31732004. View Article : Google Scholar
82	Kwee SA and Tiirikainen M: Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: Mechanisms and biomarkers. Hepatoma Res. 7:82021.PubMed/NCBI
83	Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C and Strauss M: NF-kappaB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 19:2690–2698. 1999. View Article : Google Scholar
84	Bar-Yehuda S, Madi L, Silberman D, Gery S, Shkapenuk M and Fishman P: CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia. 7:85–90. 2005. View Article : Google Scholar : PubMed/NCBI
85	Varani K, Vincenzi F, Targa M, Paradiso B, Parrilli A, Fini M, Lanza G and Borea PA: The stimulation of A(3) adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. Eur J Cancer. 49:482–491. 2013. View Article : Google Scholar
86	Frydrych I, Dolezel P and Mlejnek P: P-glycoprotein overexpression confers resistance to A3 adenosine receptor agonists 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (Cl-IB-MECA) in human leukemia cells. Purinergic Signal. 4(Suppl 1): S1–S210. 2008.
87	Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, Pulaski L, Romero IA, Couraud PO, Weksler BB, Hladky SB and Barrand MA: Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 106:1855–1865. 2008.PubMed/NCBI
88	Buschauer S, Koch A, Wiggermann P, Müller M and Hellerbrand C: Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro. Oncol Lett. 15:4635–4640. 2018.
89	Yin W, Xiang D, Wang T, Zhang Y, Pham CV, Zhou S, Jiang G, Hou Y, Zhu Y, Han Y, et al: The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells. Sci Rep. 11:107912021. View Article : Google Scholar :
90	Hoare SRJ: The problems of applying classical pharmacology analysis to modern in vitro drug discovery assays: Slow binding kinetics and high target concentration. SLAS Discov. 26:835–850. 2021.PubMed/NCBI
91	Fredholm BB: Adenosine receptors as drug targets. Exp Cell Res. 316:1284–1288. 2010. View Article : Google Scholar : PubMed/NCBI
92	Kim SG, Ravi G, Hoffmann C, Jung YJ, Kim M, Chen A and Jacobson KA: p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. Biochem Pharmacol. 63:871–880. 2002. View Article : Google Scholar : PubMed/NCBI
93	Mlejnek P, Dolezel P and Frydrych I: Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations. J Physiol Biochem. 69:405–417. 2013. View Article : Google Scholar
94	Jajoo S, Mukherjea D, Watabe K and Ramkumar V: Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia. 11:1132–1145. 2009. View Article : Google Scholar :